Product Name: ErbB2 (732-739) pY735
Product Number: PE-04AMC95
Size: 200 µg      Price:50.00
1 mg      $US100.00
5 mg      220.00
Peptide Name: ErbB2 (732-739) pY735

Product Use: Services as a blocking peptide for use with the ErbB2-pY735 rabbit polyclonal antibody (Cat. No.: AB-PK614) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the region between the Transmembrane and kinase catalytic domains. One of the major in vivo sites of phosphorylation in ErbB2. Phosphorylation induces interaction with SHC1.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: GTV-pY-KGIW

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys

Peptide Modifications Other: Phosphorylated

Peptide Molecular Mass Calculated: 1177.24 Da

Peptide Purity Percent after Synthesis and Purification: >95

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: ErbB2 - pY735 phosphosite-specific antibody (Cat. No.: AB-PK614)

Scientific Background: ErbB2 (HER2, Neu) is a protein-tyrosine kinase of the TK group and EGFR family. It is a kinase that function as a component of several membrane protein receptor complexes on the cell surface. Specifically, the ErbB2 protein functions in the regulation of the growth and stabilization of peripheral microtubules, as well as in the transcriptional activation of several rRNA genes (mediated by RNA polymerase I) that result in enhanced protein synthesis and subsequent cell growth. It is highly expressed and widely distributed in most tested human tissues except in the brain and spinal cord, where it is more moderately expressed. Protein interaction is induced with phosphorylation of Y1139 (with Grb2, Grb7 & Src), Y1196 (with Crk), and Y1222 (with CGI-27, Grb2 & Shc1). Phosphorylation of Y1112 induces interaction with Cbl, which promotes ErbB2 degradation. Overexpression of unaltered ErbB2 coding sequences in NIH-3T3 cells results in cellular transformation and tumorigenesis. ErbB2 is amplified in about 30% of primary human breast malignancies and overexpression of ErbB2 is associated with the most aggressive tumours that show uncontrolled proliferation, resistance to apoptosis and increased motility. ErbB2 has also been linked with the development of ovarian cancer, gastric and lung adenocarcinomas, and glioblastomas. Insertional mutagenesis studies in mice also support a role for this protein kinase in mouse cancer oncogenesis.